Rec'd PCT/PTO 09 MAY 2005

PATENT COOPERATION TREATY



o 11 MAY 2005

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILI

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 100896-1 WO		FOR FURTHER AC	TION	See Form PCT/IPEA/416	
l	national application No. I/SE 03/01760	International filing date (day/month/year)	Priority date (day/month/year) 15.11.2002	
	national Patent Classification (IPC K31 <i>I</i> 575	c) or national classification and IF	c		
Appli AST	Icant FRAZENECA AB				
1.	 This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36. 				
2.	2. This REPORT consists of a total of 5 sheets, including this cover sheet.				
3.	3. This report is also accompanied by ANNEXES, comprising:				
	a. \square sent to the applicant and to the International Bureau) a total of sheets, as follows:				
	sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).				
	☐ sheets which su beyond the discl Supplemental Be	osure in the international app	nich this Authority cons lication as filed, as indi	iders contain an amendment that goes cated in item 4 of Box No. I and the	
	b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)), containing sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).				
4.	4. This report contains indications relating to the following items:				
	Box No. I Basis of the	ne opinion			
	☐ Box No. II Priority				
	☐ Box No. III Non-estat	dishment of opinion with rega	rd to novelty, inventive	step and industrial applicability	
	☐ Box No. IV Lack of ur	nity of invention			
i 1					
		ocuments cited			
		efects in the international app			
	⊔ Box No. VIII Certain of	oservations on the internation	ai application		
Date of submission of the demand		Date of completion of th	is report		
25.05.2004			10.05.2005		
Name and mailing address of the international preliminary examining authority:			Authorized Officer	stricts Patherson.	
-	European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 To Fax: +49 89 2399 - 446	c: 523656 epmu d	Cattell, James Telephone No. +49 89 2	2399-8468	

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/SE 03/01760

	Box No. I	Basis of the report			
1.	With regard to the language , this report is based on the international application in the language in which it will fill fill fill fill fill fill fill				
	which □ into □ pul	eport is based on translations from the original language into the following language, is the language of a translation furnished for the purposes of: ernational search (under Rules 12.3 and 23.1(b)) blication of the international application (under Rule 12.4) ernational preliminary examination (under Rules 55.2 and/or 55.3)			
2.	have been	Nith regard to the elements* of the international application, this report is based on <i>(replacement sheets which</i> have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):			
	Description	n, Pages			
	1-6	as originally filed			
	Claims, Numbers				
	1-14	as originally filed			
	□ a sequ	uence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing			
3.	The amendments have resulted in the cancellation of: ☐ the description, pages ☐ the claims, Nos. ☐ the drawings, sheets/figs ☐ the sequence listing (specify): ☐ any table(s) related to sequence listing (specify):				
4.	had not be Supplemen the the the	eport has been established as if (some of) the amendments annexed to this report and listed below the made, since they have been considered to go beyond the disclosure as filed, as indicated in the ntal Box (Rule 70.2(c)). Independent of the disclosure as filed, as indicated in the ntal Box (Rule 70.2(c)). Independent of the disclosure as filed, as indicated in the ntal Box (Rule 70.2(c)). Independent of the disclosure as filed, as indicated in the ntal Box (Rule 70.2(c)). Independent of the disclosure as filed, as indicated in the ntal Box (Rule 70.2(c)). Independent of the disclosure as filed, as indicated in the ntal Box (Rule 70.2(c)). Independent of the disclosure as filed, as indicated in the ntal Box (Rule 70.2(c)). Independent of the disclosure as filed, as indicated in the ntal Box (Rule 70.2(c)). Independent of the disclosure as filed, as indicated in the ntal Box (Rule 70.2(c)). Independent of the disclosure as filed, as indicated in the ntal Box (Rule 70.2(c)). Independent of the disclosure as filed, as indicated in the ntal Box (Rule 70.2(c)). Independent of the disclosure as filed, as indicated in the ntal Box (Rule 70.2(c)). Independent of the disclosure as filed, as indicated in the ntal Box (Rule 70.2(c)). Independent of the disclosure as filed, as indicated in the ntal Box (Rule 70.2(c)). Independent of the disclosure as filed, as indicated in the ntal Box (Rule 70.2(c)).			
	* If it	em 4 applies, some or all of these sheets may be marked "superseded."			

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/SE 03/01760

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

7,10,11,12

No: Claims

12,3,4,5,6,8,9,13,14

Inventive step (IS)

Yes: Claims

No: Claims

1-14

Industrial applicability (IA)

Yes: Claims

1-14

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

٧.

- The documents cited in the search report are to be regarded as being numbered D1-D6 in their order of citation. The IPEA intend to refer to the sections of these documents highlighted in the search report, unless otherwise specified.
- 2). Claim 1 refers to the addition of two ingredients one after the other into a container. This would seem very similar to putting milk in one's coffee, a process which does not result in any adhesion and hence falls within the scope of claim 1 under Article 33(2) PCT. Putting water into one's whisky falls within the scope of claim 3.
- 3). D1, D3-D4 describe the mixture of two ingredients which are then filled into a container, the propellant is then added. The propellant may be regarded as a "component" of claim 2, which is therefore not novel under Article 33(2) PCT.
 - Furthermore a product is not characterised by its manufacture. D1, D3 and D4 also therefore fall within the scope of claims 9 and 10.
- 4). D2, example 1, page 8 line 7, states that the formoterol and budesonide were weighed into a can which was then filled with tetrafluoroethane and crimped. It is clear that the "can" then becomes the final metered dose inhaler, i.e. the final container.
 - The process of "weighing" each active substance into the final container must have taken place in a stepwise manner.
 - Hence D2 falls within the scope of claims 1,2,4,5,6,8,9,13, and 14 under Article 33(2) PCT.
- 5). The features of claims 7 and 10 to 12 would appear to be obvious selections of known ingredients.
- 6). The example given in the present application shows that te addition of budesonide followed by formoterol results in less adhesion. This could not have been predicted from the prior art under Article 33 PCT, but does not appear to have been clearly

International application No.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

PCT/SE 03/01760

expressed in any of the claims.

7). For the assessment of the present claims 13-14 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.